Maria Teresa Pagliari

List of Publications by Year
in descending order

18 papers	346 citations	1040056 9 h-index	839539 18 g-index
18 all docs	18 docs citations	18 times ranked	660 citing authors

#	Article	IF	Citations
1	The dominant p.Thr274Pro mutation in the von Willebrand factor propeptide causes the von Willebrand disease type 1 phenotype in two unrelated patients. Haemophilia, 2022, , .	2.1	1
2	Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERSâ€IPS study. Journal of Thrombosis and Haemostasis, 2022, 20, 1106-1114.	3.8	5
3	Phenotypic and genetic characterizations of the Milan cohort of von Willebrand disease type 2. Blood Advances, 2022, 6, 4031-4040.	5.2	5
4	The ADAMTS13â€von Willebrand factor axis in COVIDâ€19 patients. Journal of Thrombosis and Haemostasis, 2021, 19, 513-521.	3.8	176
5	ADAMTS13 activity, high VWF and FVIII levels in the pathogenesis of deep vein thrombosis. Thrombosis Research, 2021, 197, 132-137.	1.7	13
6	Role of ADAMTS13, VWF and F8 genes in deep vein thrombosis. PLoS ONE, 2021, 16, e0258675.	2.5	6
7	Evaluation of a fully automated von Willebrand factor assay panel for the diagnosis of von Willebrand disease. Haemophilia, 2020, 26, 298-305.	2.1	7
8	Risk of diagnostic delay in congenital thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2019, 17, 666-669.	3.8	4
9	The ISTH Bleeding Assessment Tool and the risk of future bleeding. Journal of Thrombosis and Haemostasis, 2018, 16, 125-130.	3.8	32
10	Differential diagnosis between type 2A and 2B von Willebrand disease in a child with a previously undescribed de novo mutation. Haemophilia, 2018, 24, e263-e266.	2.1	2
11	The D173G mutation in ADAMTS-13 causes a severe form of congenital thrombotic thrombocytopenic purpura. Thrombosis and Haemostasis, 2016, 115, 51-62.	3.4	14
12	von Willebrand disease type 1 mutation p.Arg1379Cys and the variant p.Ala1377Val synergistically determine a 2M phenotype in four Italian patients. Haemophilia, 2016, 22, e502-e511.	2.1	6
13	Next-Generation Sequencing and In Vitro Expression Study of ADAMTS13 Single Nucleotide Variants in Deep Vein Thrombosis. PLoS ONE, 2016, 11, e0165665.	2.5	7
14	Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination. Journal of Thrombosis and Haemostasis, 2015, 13, 1806-1814.	3.8	11
15	Predictors of von Willebrand disease diagnosis in individuals with borderline von Willebrand factor plasma levels. Journal of Thrombosis and Haemostasis, 2015, 13, 228-236.	3.8	18
16	The typeÂ2B p.R1306W natural mutation of von Willebrand factor dramatically enhances the multimer sensitivity to shear stress. Journal of Thrombosis and Haemostasis, 2013, 11, 1688-1698.	3.8	15
17	A synonymous (c.3390C>T) or a spliceâ€site (c.3380â€2A>G) mutation causes exonÂ26 skipping in four patients with von Willebrand disease (2A/IIE). Journal of Thrombosis and Haemostasis, 2013, 11, 1251-1259.	3.8	15
18	Interferon-Î² but not Glatiramer acetate stimulates CXCL10 secretion in primary cultures of thyrocytes: A clue for understanding the different risks of thyroid dysfunctions in patients with multiple sclerosis treated with either of the two drugs. Journal of Neuroimmunology, 2011, 234, 161-164.	2.3	9